TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22944596

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 177

Group type: COMPARATOR
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: DYS at 1 month
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: RVA pacing
Number of subjects: 177
Study: 21732110

Group type: EXPERIMENTAL
Intervention: Canaloplasty
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Combined cataract-canaloplasty surgery
Number of subjects: 109

Group type: COMPARATOR
Intervention: All study eyes
Number of subjects: 109
Study: 20028262

Group type: EXPERIMENTAL
Intervention: 0.5 mg intravitreal ranibizumab (IVR) injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 16954164

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 9
Study: 15105192

Group type: COMPARATOR
Intervention: Metoprolol 10 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Metoprolol 20 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Metoprolol 30 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 11368733

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate, 42 microg twice per day (salmeterol‐minus group)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Salmeterol xinafoate, 42 microg twice per day (salmeterol‐plus group)
Number of subjects: 175
Study: 9038597

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (free phenol form)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RRR-alpha-tocopherol and RRR-alpha-tocopheryl acetate (administered in equal doses)
Number of subjects: 0
Study: 8316388

Group type: EXPERIMENTAL
Intervention: Bier's block with 0.6 mg of atropine in 10 ml of saline
Number of subjects: 33

Group type: COMPARATOR
Intervention: 10 ml of saline
Number of subjects: 33
Study: 3555034

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg orally every 12 hours (or 500 mg for the 13-year-old) for 2 to 8 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tobramycin and azlocillin administered intravenously for at least two weeks
Number of subjects: 12
Study: 29394325

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (1 mA for 20 min on five consecutive days) combined with speech fluency intervention (choral and metronome-timed speech)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation combined with speech fluency intervention (choral and metronome-timed speech)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (1 mA for 20 min on five consecutive days) combined with speech fluency intervention
Number of subjects: 30
Study: 27472855

Group type: EXPERIMENTAL
Intervention: Stabilization exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine exercise
Number of subjects: 40
Study: 26554670

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) in addition to Tinnitus Retraining Therapy (TRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS) in addition to Tinnitus Retraining Therapy (TRT)
Number of subjects: 0
Study: 23589371

Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg twice a day
Number of subjects: 140
Study: 21551007

Group type: EXPERIMENTAL
Intervention: High-fat diet with endurance training in fasted state (n = 10)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-fat diet with endurance training in carbohydrate-fed state (n = 10)
Number of subjects: 27

Group type: COMPARATOR
Intervention: High-fat diet without training (control group, n = 7)
Number of subjects: 27
Study: 18451391

Group type: EXPERIMENTAL
Intervention: Two-incision total hip arthroplasty
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mini-posterior-incision total hip arthroplasty
Number of subjects: 72
Study: 16921788

Group type: EXPERIMENTAL
Intervention: Oral estradiol 2 mg/day for 12 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 microg/day (7-day patches) for 12 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison between oral and transdermal therapy
Number of subjects: 41
Study: 12915972

Group type: EXPERIMENTAL
Intervention: HT Immersion Medical Colonoscopy Simulator (module 3 or 4)
Number of subjects: 25
Study: 11120762

Group type: EXPERIMENTAL
Intervention: Physiologic T and E replacement
Number of subjects: 59

Group type: COMPARATOR
Intervention: Withdrawal of both T and E
Number of subjects: 59

Group type: COMPARATOR
Intervention: Withdrawal of only T
Number of subjects: 59

Group type: COMPARATOR
Intervention: Withdrawal of only E
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Continuing both T and E
Number of subjects: 59
Study: 9212967

Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 14

Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pulsatile pump
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 14
Study: 8427165

Group type: EXPERIMENTAL
Intervention: Encainide and flecainide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3669283

Group type: EXPERIMENTAL
Intervention: Cefuzonam (CZON) administered by intravenous injection or intravenous drip infusion, 1 g twice daily for 4 to 7 days (8 g to 14 g in total)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cefuzonam (CZON)
Number of subjects: 13
Study: 29754930

Group type: EXPERIMENTAL
Intervention: short time flow-mediated vasodilation (stFMD)
Number of subjects: 82
Study: 28358178

Group type: EXPERIMENTAL
Intervention: Storz® C‐MAC™ videolaryngoscopy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Direct laryngoscopy (Macintosh®)
Number of subjects: 80
Study: 26410046

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) with modern medical treatment (MMT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Modern medical treatment (MMT) alone
Number of subjects: 55
Study: 23410803

Group type: EXPERIMENTAL
Intervention: Enhanced Condition (N = 857)
Number of subjects: 1716

Group type: COMPARATOR
Intervention: Basic Condition (N = 859)
Number of subjects: 1716
Study: 21397567

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (24 mg per day or 12 mg per day intravenously for 2 or 3 annual cycles)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Interferon beta-1a (44 μg subcutaneously three times per week)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (for patients with baseline EDSS ≥2)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Interferon beta-1a (for patients with baseline EDSS ≥2)
Number of subjects: 334
Study: 18347652

Group type: EXPERIMENTAL
Intervention: Protein-enriched recovery (0.7 g.kg(‐1).h(‐1) protein)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control recovery (0.1 g.kg(‐1).h(‐1) protein)
Number of subjects: 12
Study: 17015500

Group type: EXPERIMENTAL
Intervention: Home-based mentoring intervention (biweekly until the infant's first birthday)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Home-based mentoring intervention (having > or = 2 intervention visits)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Home-based mentoring intervention (having > or = 6 visits)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Home-based mentoring intervention
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 181
Study: 12694140

Group type: EXPERIMENTAL
Intervention: Slow rewarming (0.24 +/- 0.09 degrees C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (0.48 +/- 0.09 degrees C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mini-mental state examination scores
Number of subjects: 100
Study: 14728824

Group type: EXPERIMENTAL
Intervention: Anticoagulants therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no anticoagulants)
Number of subjects: 86
Study: 10678121

Group type: EXPERIMENTAL
Intervention: Huperzine-A capsules (Hup) 50 micrograms, 2 capsules b.i.d. for 4 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (starch and lactose), 2 capsules b.i.d. for 4 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Huperzine-A capsules (Hup)
Number of subjects: 68
Study: 8932546

Group type: EXPERIMENTAL
Intervention: Mizolastine 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mizolastine 15 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1875406

Group type: EXPERIMENTAL
Intervention: Combined treatment groups (n = 25)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Assessment only control group (n = 9)
Number of subjects: 25
Study: 6342360

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Peer support therapy group
Number of subjects: 81
Study: 3485932

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 219

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 219
Study: 31606887

Group type: EXPERIMENTAL
Intervention: Psychoeducation program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study: 29413495

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41
Study: 28150856

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) in addition to pulmonary rehabilitation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation alone
Number of subjects: 70
Study: 26714460

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) - two gym-based supervised sessions/week and one home-based session/week, consisting of four 4-minute intervals at approximately 90% of maximum heart rate with 3-minute recovery periods.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle physical activity - participants receive a resource pack and pedometer, aiming to increase daily steps to 10,000 steps/day.
Number of subjects: 0
Study: 23988418

Group type: EXPERIMENTAL
Intervention: DBGT (double-brewed green tea), 500 mL daily until recurrence or during a follow-up of 18 months
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DBGT adherence
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DBGT intervention
Number of subjects: 16
Study: 21996391

Group type: EXPERIMENTAL
Intervention: Supervised endurance/resistance training in addition to usual care (ET, n = 44)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care alone (UC, n = 20)
Number of subjects: 64
Study: 18423747

Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 16503680

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training (30 seconds at 28 Hz, 10-mm amplitude, 6 times per training session) combined with contract-release stretching
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (contract-release stretching only)
Number of subjects: 19
Study: 12758210

Group type: EXPERIMENTAL
Intervention: NTP regimen
Number of subjects: 360

Group type: COMPARATOR
Intervention: 4FDC regimen
Number of subjects: 360
Study: 11010055

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 187

Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 187
Study: 9059293

Group type: EXPERIMENTAL
Intervention: Power Doppler sonography
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Biopsy results
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Statistical analysis
Number of subjects: 22
Study: 8420606

Group type: EXPERIMENTAL
Intervention: Mammographic film classified as P2 or DY
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormality reported by radiologist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abnormality reported by nurse examiner
Number of subjects: 0
Study: 3773721

Group type: EXPERIMENTAL
Intervention: Aerobic training program (3 d/wk, 48 min/d, at 65% to 85% of heart rate reserve)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aerobic training program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (untrained state)
Number of subjects: 34
Study: 31740428

Group type: EXPERIMENTAL
Intervention: GKT137831 400 mg BID for 48 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 29329422

Group type: EXPERIMENTAL
Intervention: Proscriptive health message
Number of subjects: 529

Group type: COMPARATOR
Intervention: Prescriptive health message
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Proscriptive health message (for male participants drinking above recommended limits)
Number of subjects: 529
Study: 27298017

Group type: EXPERIMENTAL
Intervention: Lumacaftor (600 mg once daily) plus ivacaftor (250 mg every 12 h)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Lumacaftor (400 mg every 12 h) plus ivacaftor (250 mg every 12 h)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Lumacaftor (600 mg per day) plus ivacaftor (250 mg every 12 h)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Lumacaftor (400 mg/12 h) plus ivacaftor (250 mg every 12 h)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor (both doses)
Number of subjects: 1108

Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1108
Study: 24571855

Group type: EXPERIMENTAL
Intervention: Tactile acuity training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (sham tactile acuity training)
Number of subjects: 15
Study: 23765950

Group type: EXPERIMENTAL
Intervention: Severe eosinophilia (≥ 1.0 × 10(9) /L)
Number of subjects: 356196

Group type: EXPERIMENTAL
Intervention: Mild eosinophilia (≥ 0.5‐1.0 × 10(9) /L)
Number of subjects: 356196

Group type: EXPERIMENTAL
Intervention: Any eosinophilia
Number of subjects: 356196
Study: 20225703

Group type: EXPERIMENTAL
Intervention: Micronutrient mixture (alpha‐tocopherol acetate, ascorbic acid, cholecalcipherol, green tea extract)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Micronutrient mixture
Number of subjects: 32
Study: 17959703

Group type: EXPERIMENTAL
Intervention: Bradykinin infusion
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion
Number of subjects: 47
Study: 16983396

Group type: EXPERIMENTAL
Intervention: Whole-tomato lycopene supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14733451

Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine (10.0 mg)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol (7.5 mg)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 311
Study: 10883158

Group type: EXPERIMENTAL
Intervention: Daily i.v. glucosamine sulfate (GS) together with 800 mg chondroitin sulfate for 4 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 9085297

Group type: EXPERIMENTAL
Intervention: Mental Arithmetic (MA) followed by Cold Pressor Task (CP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cold Pressor Task (CP) followed by Mental Arithmetic (MA)
Number of subjects: 52
Study: 8255520

Group type: EXPERIMENTAL
Intervention: Ganciclovir (5 mg/kg b.i.d./day for 14 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no ganciclovir)
Number of subjects: 32
Study: 3987531

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, retard form)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Verapamil (160 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg)
Number of subjects: 44
Study: 31301210

Group type: EXPERIMENTAL
Intervention: Obese pubertal youth
Number of subjects: 421

Group type: COMPARATOR
Intervention: Obese adults
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 421

Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) and high-density lipoprotein (HDL) cholesterol in adults
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) and high-density lipoprotein (HDL) cholesterol in youth
Number of subjects: 421
Study: 28340516

Group type: EXPERIMENTAL
Intervention: High Protein/Low Fat (55%C/25%P/20%F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High Protein/High Fat (35%C/25%P/40%F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low Protein/High Fat (45%C/15%P/40%F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low Carbohydrate (65%C/15%P/20%F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowest Carbohydrate Group
Number of subjects: 0
Study: 25956480

Group type: EXPERIMENTAL
Intervention: CF+ group (with CF measuring catheter)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CF- group (without CF measuring catheter)
Number of subjects: 36
Study: 22959318

Group type: EXPERIMENTAL
Intervention: 5% dextrose in normal saline solution
Number of subjects: 188

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 188
Study: 22088178

Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Amino acid formula
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All hypoallergenic formulae
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Amino acid formula and extensively hydrolyzed formula
Number of subjects: 74
Study: 19344615

Group type: EXPERIMENTAL
Intervention: Otoacoustic emission (OAE) testing
Number of subjects: 8

Group type: COMPARATOR
Intervention: Audiometry
Number of subjects: 8
Study: 16688058

Group type: EXPERIMENTAL
Intervention: Helmeted motorcyclists
Number of subjects: 5328

Group type: COMPARATOR
Intervention: Unhelmeted motorcyclists
Number of subjects: 5328

Group type: COMPARATOR
Intervention: Cost comparison
Number of subjects: 5328

Group type: COMPARATOR
Intervention: Overall economic burden
Number of subjects: 5328
Study: 12630019

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 193
Study: 10711881

Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Extracapsular cataract surgery
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Phacoemulsification and Extracapsular cataract surgery
Number of subjects: 46
Study: 9360566

Group type: EXPERIMENTAL
Intervention: Premixed slurry of deferoxamine mesylate (DFO) and activated charcoal (AC) with 5 mg/kg ferrous sulfate and 8 g of DFO and 25 g of 20% AC
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg/kg ferrous sulfate alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg/kg ferrous sulfate added to 25 g of 20% AC
Number of subjects: 0
Study: 1492440

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional or no antiarrhythmic therapy
Number of subjects: 30
Study: 4028957

Group type: EXPERIMENTAL
Intervention: Instruction in coping techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no instruction)
Number of subjects: 0
Study: 31900475

Group type: EXPERIMENTAL
Intervention: Tilapia skin xenograft dressing
Number of subjects: 62

Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 62
Study: 29429138

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: amisulpride
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: SCN5A (H558R)
Number of subjects: 199

Group type: COMPARATOR
Intervention: KCNH2, KCNQ1, LOC10537879, LOC101927066, NOS1AP, NUBPL polymorphisms
Number of subjects: 199
Study: 25529554

Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment (CGT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 69
Study: 24513787

Group type: COMPARATOR
Intervention: Interleukin‐2 receptor antagonists (daclizumab or basiliximab)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG)
Number of subjects: 200
Study: 23056520

Group type: EXPERIMENTAL
Intervention: Acidform gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: HEC placebo gel
Number of subjects: 36
Study: 20565956

Group type: EXPERIMENTAL
Intervention: Whole body vibration exercises (1 hour, 3 times a week for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy (1 hour, 3 times a week for 6 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Whole body vibration exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 40
Study: 17548760

Group type: EXPERIMENTAL
Intervention: School-based fitness curriculum
Number of subjects: 0
Study: 15897266

Group type: EXPERIMENTAL
Intervention: Large pictograms
Number of subjects: 227

Group type: COMPARATOR
Intervention: Small pictograms
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Second presentation of pictograms
Number of subjects: 227
Study: 12784968

Group type: EXPERIMENTAL
Intervention: Logistic regression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ordinal logit regression model
Number of subjects: 0
Study: 9607246

Group type: EXPERIMENTAL
Intervention: Health education (HE) from family doctor
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (CG) of 55 patients who received HE from their family doctor
Number of subjects: 110